Advertisement

Topics

Cambridge Drug Discovery Company Profile

01:50 EDT 23rd September 2017 | BioPortfolio

Cambridge Drug Discovery, CDD, focus on the discovery of small molecules that modify cellular signalling. We are developing new assay methodologies for ion channels, GPCRs and kinases targets, including the application of our proprietary retroviral technology to develop new screening systems. Our expanding library collection of quality, diverse compounds (currently 100,000) and automated HTS system enables us to offer an integrated gene to screen service. Underpinning our gene to screen efforts is CDD's proprietary database, TargetBASE™ that encompasses bioinformatics and cheminformatics to integrate target and screening data. TargetBASE™ is a unique standalone product that is readily accessible for customised target analysis and selection.

CDD currently have 42 staff, including over 25 post-doctoral industrially trained scientists. Our purpose-built laboratories cover 12,000 sq ft and are located along side our administration building, on the Cambridge Science Park, Cambridge, UK.



CDD's core business is to provide drug discovery services and access to its technology portfolio through strategic outsourcing initiatives with biotech and pharmaceutical companies. Our internal R&D programme is focused on validating new technologies and identifying hit compounds from the CDD compound collection, for subsequent partnering programs. We expect to be in a position to partner lead compounds at the end of this year.

Location

Cambridge Science Park, Milton Rd
Cambridge
Cambridgeshire
CB4 0FG
United Kingdom

Contact

Phone: 01223 723 222
Fax: 01223 723 223
Email: sales@camdd.co.uk


News Articles [4794 Associated News Articles listed on BioPortfolio]

Consortium Applies Quantum Computing to Drug Discovery for Neurological Diseases

NewsMolecular comparison is a crucial part of early-phase drug design and discovery.

Cambridge start-up secures £40 million to trial innovative cancer drugs

Bicycle Therapeutics, a biotech start-up based in Cambridge, UK, has just raised £40 million from a range of investors including Cambridge Innovation Capital (CIC) in order to push its cancer drug ca...

#jobs #lifescience AstraZeneca – Cambridge: RDSC – Senior Scientist, Drug Product Delivery

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: AstraZeneca – Cambridge: RDSC – Senior Scientist, Drug Product De...

Cancer research: 3-D models accommodate better precision in drug discovery

The field of cancer research is moving rapidly toward three-dimensional (3D) laboratory cultures because 3D models can speed drug discovery and better predict the efficacy of using certain drug therap...

#jobs #lifescience AstraZeneca – Cambridge: Scientist/Senior Scientist – Drug Product Manufacture

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: AstraZeneca – Cambridge: Scientist/Senior Scientist – Drug Produc...

#jobs #lifescience AstraZeneca – Cambridge: RDSC – Associate Principal Scientist – Drug Product Delivery

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: AstraZeneca – Cambridge: RDSC – Associate Principal Scientist ...

GlaxoSmithKline and Exscientia enter strategic drug discovery collaboration

Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK). During t...

BenevolentAI hires Ian Churcher as VP of Drug Discovery & Preclinical Development

BenevolentAI, one of the world’s largest private AI companies, has hired Dr. Ian Churcher as its new VP of Drug Discovery & Preclinical Development of its bioscience subsidiary BenevolentBio. Ia...

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Caraderma [A Refreshing Discovery, Inc.]

CaraDerma acne treatment

Polocaine [Dentsply Pharmaceutical]

3% Polocaine DENTAL (Mepivacaine Hydrochloride Injection, USP) 2% Polocaine DENTAL with Levonordefrin 1:20,000 (Mepivacaine Hydrochloride and Levonordefrin Injection, USP)

Xylocaine [Dentsply Pharmaceutical]

2% Xylocaine DENTAL with epinephrine 1:50,000 (Lidocaine HCl 2% and Epinephrine 1:50,000 Injection) 2% Xylocaine DENTAL with epinephrine 1:100,000 (Lidocaine HCl 2% and Epinephrine 1:100,000 Injection...

Articadent [Dentsply Pharmaceutical]

4% Articadent™ DENTAL with epinephrine 1:100,000 (Articaine hydrochloride 4% (40mg/mL) with epinephrine 1:100,000 injection) 4% Articadent™ DENTAL with epinephrine 1:200,000 (Articaine hydrochlori...

Gastromark [Mallinckrodt Inc.]

February 2010 300 mL 175 μg Fe/mL Gastromark™ [ferumoxsil, oral suspension] Mallinckrodt Inc. Rx only

PubMed Articles [4197 Associated PubMed Articles listed on BioPortfolio]

Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.

There was a greater than 50% decline in central nervous system (CNS) drug discovery and development programs by major pharmaceutical companies from 2009 to 2014. This decline was paralleled by a rise ...

From machine learning to deep learning: progress in machine intelligence for rational drug discovery.

Machine intelligence, which is normally presented as artificial intelligence, refers to the intelligence exhibited by computers. In the history of rational drug discovery, various machine intelligence...

Fragment-Based Drug Discovery of Phosphodiesterase Inhibitors.

Phosphodiesterases are proving to be fruitful targets for drug discovery. At the same time fragment-based drug discovery has matured into a powerful and widely applied technique. In this communication...

Kinetics for Drug Discovery: an industry-driven effort to target drug residence time.

A considerable number of approved drugs show non-equilibrium binding characteristics, emphasizing the potential role of drug residence times for in vivo efficacy. Therefore, a detailed understanding o...

Discovery and Development of Novel Drugs.

Drug discovery and development process is nowadays conducted in relatively standardised sequence of phases, starting with Discovery and being followed by Preclinical, Clinical and Non-Clinical Develop...

Clinical Trials [2016 Associated Clinical Trials listed on BioPortfolio]

Discovery Elbow Multi-Center Prospective Study

The purpose of this prospective clinical trial is to document the performance and clinical outcomes of Biomet Discovery Elbow.

A Clinical Investigation of the Discovery™ Elbow System

The purpose of this study is to perform a five-year, multi-center prospective evaluation of the Discovery™ Elbow System for outcome and durability. Relief of pain and restoration of fun...

Endometriosis Biomarker Discovery Study

This is a prospective, Single time point, discovery study intending to identify biomarkers that can differentiate endometriosis from other underlying reasons for pelvic pain. Patients unde...

Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma

The purpose of the study is to better understand the function of asthma and COPD, and response to therapy. There are two Phases to this study broken into two arms. In Phase I, our propose ...

Color Vision as a Measure for Inherited Retinal Diseases

Background: - The purpose of this study is to find out whether color vision measured with the Cambridge Color Test is a good way to examine the severity of inherited retinal diseases (IRD...

Companies [2583 Associated Companies listed on BioPortfolio]

Sentinel Oncology Limited

Sentinel Oncology was founded in 2005 with the vision of developing an innovative strategy for cancer treatment, ‘Targeted Synergy’ in which a single drug can be engineered to deliver tw...

Cambridge Drug Discovery

Cambridge Drug Discovery, CDD, focus on the discovery of small molecules that modify cellular signalling. We are developing new assay methodologies for ion channels, GPCRs and kinases targets, includ...

Domainex

Domainex — reducing drug discovery timelines, maintaining quality. Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug...

Ligon Discovery

Ligon Discovery is a Harvard University spinout that leverages a patented platform technology to identify pre-clinical drug candidates. The company's high-throughput microarray "chip" transforms the s...

Astex Therapeutics

Astex was founded in 1999 by Harren Jhoti, PhD, former Head of Structural Biology and of UK Bioinformatics at GlaxoWellcome, together with Professor Sir Tom Blundell, FRS, Professor Chris Abell, (both...

More Information about "Cambridge Drug Discovery" on BioPortfolio

We have published hundreds of Cambridge Drug Discovery news stories on BioPortfolio along with dozens of Cambridge Drug Discovery Clinical Trials and PubMed Articles about Cambridge Drug Discovery for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambridge Drug Discovery Companies in our database. You can also find out about relevant Cambridge Drug Discovery Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Assays
An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...


Corporate Database Quicklinks



Searches Linking to this Company Record